ORGALUTRAN 0.25MG /0.5ML

Product Description
Orgalutran is a solution for injection in a prefilled syringe. Each syringe contains 0.25 mg of the active substance, ganirelix.
Orgalutran is used to prevent premature ovulation (early release of eggs from the ovary) in women having fertility treatment and who are having ovarian stimulation (stimulation of the ovaries so that they produce more eggs). In premature ovulation, the ovaries release eggs that may be immature and not suitable for use in techniques such as in-vitro fertilisation.
The medicine can only be obtained with a prescription.
How is it used?
Treatment with Orgalutran should be carried out by a doctor who has experience in this type of fertility treatment.
Orgalutran is given as a single 0.25-mg injection under the skin once a day. Treatment should start on day 5 or 6 after the start of ovarian stimulation with follicle stimulating hormone (FSH) or corifollitropin alfa (a modified FSH). When treatment should start depends on how well the ovaries are responding to stimulation. Treatment with Orgalutran should be continued up to the day that there are enough large follicles (small sacs in the ovary that hold the eggs).
Orgalutran is preferably given into the upper leg. The patient or her partner may give the injections themselves, if they have been trained and have access to expert advice. For further information on how to use Orgalutran, see the package leaflet.
Orgalutran 0.25 mg/0.5 ml solutie injectabila
Orgalutran Soln.For Inj. 0.25Mg/0.5Ml 1 Syr
Hormonal Treatment
How To Use:
As prescribed
Orgalutran for IVF: Purpose, Indications and Application
Orgalutran is a hormone-type drug whose active ingredient is ganirelix, a GnRH antagonist.
GnRH is the gonadotropin-releasing hormone, which is secreted by the hypothalamus in our brain to regulate a woman's menstrual cycle. Drugs analogous to this natural hormone are so expensive due to the difficulty of synthesizing GnRH exogenously.
This medicine is used in patients who are beginning assisted reproduction treatment. Specifically, Orgalutran is necessary for controlled ovarian stimulation, both for artificial insemination (AI) and in vitro fertilization (IVF).
Below you have an index with the 8 points we are going to deal with in this article.
Active ingredients
0.25 mg ganirelix
Auxiliary materials
Acetic acid for pH adjustment
Mannitol
Water for injections
Sodium hydroxide for pH adjustment
More product information
Indication / application
The drug belongs to a group of drugs called "gonadotropin-releasing hormone antagonists", which inhibit the effects of natural gonadotropin-releasing hormone (GnRH). GnRH regulates the release of gonadotropins (luteinizing hormone [LH] and follicle-stimulating hormone [FSH]. Gonadotropins play an important role in human fertility and reproduction. In women, FSH is responsible for the growth and development of the follicles in the ovaries. Follicles are small round vesicles that contain the egg cells. LH is required for the release of mature eggs from the follicles and ovaries (ovulation). The drug prevents GnRH from working, which in particular inhibits the release of LH.
The medicine is used
Women who are undergoing artificial insemination (assisted reproduction), including in vitro fertilization (IVF) and other methods, may occasionally ovulate too early, with a significant decrease in the chance of becoming pregnant brings. The medicine is used to prevent the premature LH surge, and therefore premature ovulation.
In clinical trials, the medicine was used with recombinant follicle-stimulating hormone (FSH) or corifollitropin alfa, a long-acting follicle stimulant.
dosage
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The drug is used in assisted reproductive medicine (ART), including in vitro fertilization (IVF).
Follicle stimulating hormone (FSH) or corifollitropin stimulation of the follicles can begin on day 2 or 3 of your period. The drug (0.25 mg) should be injected just under the skin once a day, starting on the 5th or 6th day of stimulation. Depending on your ovarian response, the doctor may decide to start FSH treatment on a different day.
The drug should not be mixed with FSH, but both preparations should be given at approximately the same time, but not in the same place.
Daily treatment with ganirelix should be continued until the day when sufficient follicles of the appropriate size are present. The final maturation of the egg cells in the follicles can be initiated by administering human chorionic gonadotropin (hCG). The time between two injections and between the last ganirelix injection and the hCG injection should not exceed 30 hours, as this can lead to premature ovulation (release of the eggs). Therefore, if Ganirelix is ​​injected in the morning, Ganirelix